drugset / Trial / NCT02605486

Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

NCT02605486

Phase 1/2 Active not recruiting 46 enrolled Memorial Sloan Kettering Cancer Center Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety and effectiveness of the investigational drug, palbociclib with bicalutamide for the treatment of triple negative, androgen receptor positive breast cancer.

Timeline

Start
2015-11-11
Primary completion
2026-11
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified Oral
Subject Palbociclib Small molecule Oral

Indications